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ABSTRACT
Background Mutations in the KIAA2022 gene have
been reported in male patients with X-linked intellectual
disability, and related female carriers were unaffected.
Here, we report 14 female patients who carry a
heterozygous de novo KIAA2022 mutation and share a
phenotype characterised by intellectual disability and
epilepsy.
Methods Reported females were selected for genetic
testing because of substantial developmental problems
and/or epilepsy. X-inactivation and expression studies
were performed when possible.
Results All mutations were predicted to result in a
frameshift or premature stop. 12 out of 14 patients had
intractable epilepsy with myoclonic and/or absence
seizures, and generalised in 11. Thirteen patients had mild
to severe intellectual disability. This female phenotype
partially overlaps with the reported male phenotype which
consists of more severe intellectual disability, microcephaly,
growth retardation, facial dysmorphisms and, less
frequently, epilepsy. One female patient showed completely
skewed X-inactivation, complete absence of RNA
expression in blood and a phenotype similar to male
patients. In the six other tested patients, X-inactivation was
random, conﬁrmed by a non-signiﬁcant twofold to
threefold decrease of RNA expression in blood, consistent
with the expected mosaicism between cells expressing
mutant or normal KIAA2022 alleles.
Conclusions Heterozygous loss of KIAA2022 expression
is a cause of intellectual disability in females. Compared
with its hemizygous male counterpart, the heterozygous
female disease has less severe intellectual disability, but is
more often associated with a severe and intractable
myoclonic epilepsy.
INTRODUCTION
KIAA2022 is a known X-linked intellectual disabil-
ity (XLID) gene, with pathogenic variants causing
severe intellectual disability (ID) in males. Other,
more variable features include epilepsy, postnatal
growth retardation, autistic behaviour, strabismus
and dysmorphic facial features. The ﬁrst descrip-
tion of alterations in this gene causing ID was in
two related male patients, where both KIAA2022
and P2YR8 were interrupted by a pericentric inver-
sion of the X chromosome (Inv X(p22;p13.2)), as
reported by Cantagrel et al.1 One breakpoint was
mapped to the ﬁrst intron of KIAA2022 and was
predicted to disrupt the gene. A complete loss of
KIAA2022 expression in lymphocytes was shown.
Other reported KIAA2022 pathogenic variants
include a microduplication of exon 1, a duplication
of the entire gene and several truncating mutations,
all leading to reduced KIAA2022 expression.2–5
Limited data about KIAA2022 gene function are
available, but it is thought to have an important
role in early brain development.1 2 6–8
Female relatives carrying the KIAA2022 disruptions
identiﬁed in reported males were all unaffected.1 2 5
Nevertheless, a few affected female patients have
recently been described.9–11 Here, we report 14
female patients with heterozygous de novo mutations
of KIAA2022. All mutations result in a frameshift or
premature stop codon, predicting complete loss of
function (LOF) of the protein. Twelve patients had
epilepsy, of which eleven generalised, and all but one
patient had mild to severe ID. These data strongly
suggest that pathogenic KIAA2022 variants can lead
to a phenotype in males and in females.
METHODS
Patients
All 14 reported females were selected for genetic
testing because of their substantial developmental
problems and/or epilepsy. In 10 patients, exome
sequencing was performed, using methods that were
described previously,12–14 of which 9 were diagnos-
tic and 1 was in a research setting (patient 4).i
iPatients 7 and 12 are also being described in a
manuscript currently under review: De novo loss of
function mutations in KIAA2022 are associated with
seizures and developmental delay in females by Rachel
Webster, Megan T. Cho, Kyle Retterer, Francisca Millan,
Catherine Nowak, Jessica Douglas, Ayesha Ahmad,
Amber Begtrup, Dianalee McKnight, Orrin Devinsky,
Wendy K. Chung.
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In patient 9, a whole genome sequencing was performed in a
research setting, as previously described.15 Patient 5 was part of a
research series of 209 cases with Dravet(-like) syndrome or myo-
clonic atonic epilepsy who were selected for candidate gene
screening with a gene panel using molecular inversion probes
(MIPS) as described previously.16 Patient 8 was diagnosed after a
diagnostic array CGH (Agilent 180 k chip) indicated a microdele-
tion disrupting KIAA2022. Patient 11 was diagnosed after a
KIAA2022 mutation was identiﬁed with her two sons with ID,
through sequencing of a diagnostic ID-related gene panel.
X-inactivation and expression studies were performed when pos-
sible (X-chromosome inactivation, XCI: patients 1, 2, 3, 4, 6, 8,
9; expression studies: patients 1, 3, 4, 5, 6).
See online supplemental material for extensive details on the
molecular analyses (see online supplementary appendix 1).
Detailed clinical data were collected from medical records.
The study was approved by the ethical committees of the
respective local institutions.
Literature search
A literature study was carried out in the PubMed database to
identify previously described patients with KIAA2022 mutations.
Resulting articles and their references were screened for
reported patients with KIAA2022 mutations.
RESULTS
Clinical description
Clinical characteristics of the 14 new and 3 previously described
female patients with de novo KIAA2022 mutations are sum-
marised and compared with the clinical characteristics of previ-
ously reported males in tables 1 and 2. Table 3 gives further
details with respect to the epilepsy phenotype of the female
patients. See supplemental material for extensive clinical
descriptions of each patient (see online supplementary appendix
2). In summary, 12 out of the 14 new patients had intractable
epilepsy with myoclonic and/or absence seizures. In 11 patients,
epilepsy was generalised. Thirteen patients had mild to severe
ID. Developmental delay preceded epilepsy onset in six indivi-
duals. Behavioural problems, such as autism, aggression and
hyperactivity, were present in 10 patients. Other ﬁndings were
hypotonia, neonatal feeding difﬁculties, microcephaly and mild
dysmorphic facial features.
Molecular analysis
KIAA2022 mutations
Thirteen patients carried a de novo truncating mutation in
KIAA2022 (NM_001008537.2) (table 1). In one patient, a dele-
tion of the complete non-coding exon 1 was identiﬁed by array
CGH, which is likely to affect the expression of the protein.
Figure 1 represents the genomic organisation of the KIAA2022
gene, as well as the location of the mutations reported previ-
ously and those presented here. All mutations were absent from
the Exome Aggregation Consortium (ExAC) database (URL:
http://exac.broadinstitute.org) (accessed October 2015).17 All
sequence alterations are in the large exon 3 (coding exon 2) and
are predicted to activate non-sense mediated decay (NMD),
with one recurrent mutation, p.Arg322*, that is present in one
of the currently described females (patient 4), one male patient3
and one previously reported female.11 Overall, there seems to
be no particular domain in which mutations cluster, consistent
with the hypothesis that these truncating.
mutations all cause LOF of KIAA2022, regardless of their pos-
ition in the protein.
Chromosome X-inactivation studies and KIAA2022 expression
X-inactivation was tested in seven patients and was found to be
random in patients 1, 2, 3, 4, 8 and 9. One patient (patient 6)
showed 100% skewing. We further tested KIAA2022 expression
using digital droplet PCR of RNA derived from whole blood of
four patients (patients 1, 3, 4 and 5) and compared it with four
healthy female controls. KIAA2022 expression in blood was
expressed as a ratio of KIAA2022 mRNA copies compared with
GAPDH and was found to be low in both cases and controls.
Cases had on average a two to three times lower expression
than female controls, but this was not statistically signiﬁcant
(non-parametric test on ratio of cases vs controls, p=0.486;
ﬁgure 2). Expression of KIAA2022 in patient 6 was tested using
qPCR and was found to be completely absent.
Previously described patients
A literature search resulted in 13 publications on KIAA2022. Of
these, seven reported patients with sequence alterations of
KIAA2022 or structural X-chromosome abnormalities affecting
KIAA2022,1–3 5 9–11 whereas the other six did not describe
patients. In these ﬁrst seven publications, 15 male patients were
described. Clinical characteristics are given in table 2. Five
affected males from one family5 are excluded from the table,
because only limited clinical data were available. Three female
patients affected by KIAA2022 disruptions have previously been
reported,9–11 two with a phenotype comparable with that in
males, and one with mild ID. Clinical characteristics are given in
tables 1 and 3.
KIAA2022 mutations in public databases
All mutations reported in the currently described females were
absent from public databases. However, a few other truncation
variants have been reported. In the ExAC database, three female
and one male subjects out of a total of 60 706 subjects are
reported to have heterozygous apparent LOF variants in
KIAA2022 (hg19, NM_001008537.2), namely, chrX:
g.73959335T>C (c.4458-2A>G; one female, resulting in a
putative disruption of the canonical splice acceptor site for the
last exon), chrX:g.73959987G>A (c.4405C>T or p.Arg1469*;
two females, located right at the end of the encoded protein)
and chrX:g.73961129_73961139delCTCTCACATCT (p.Arg
1085TyrfsTer45; one hemizygous male).
DISCUSSION
We report 14 female patients with a heterozygous de novo
mutation of the X-chromosomal KIAA2022 gene. Thirteen
mutations resulted in a frameshift or premature stop codon that
can elicit NMD, predicting a complete LOF of the protein. The
14th mutation is a complete deletion of the non-coding exon 1,
most likely affecting the expression of the protein. KIAA2022
mutations and alterations have previously been reported in
males with severe ID,1–3 5 and it is an established XLID gene.
We show that KIAA2022 mutations can also cause a phenotype
in females. Overall, 11 of our female patients with KIAA2022
loss-of-function mutations showed a similar clinical phenotype,
which added to our belief that these mutations were indeed
responsible for their phenotype. This phenotype was charac-
terised by intractable epilepsy with predominant myoclonic sei-
zures and/or absences, with onset in infancy or early childhood,
behavioural problems and mild to severe ID. Developmental
delay preceded epilepsy onset in six individuals. Hypotonia,
neonatal feeding difﬁculties, microcephaly and mild dysmorphic
facial features were less frequent ﬁndings.
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Table 1 Clinical description of female cases presented carrying KIAA2022 mutations
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Ref. 9 Ref. 10 Ref. 11
Age (years) 26 9 25 11 36 2,5 9 18 5,5 2,3 53 11 51
(deceased)
8,5 26 13 17
Mutation c.4185del
p.Lys 1396fs
c.438 C>A
p.Cys 146*
c.2042del
p.Gly
681fs
c.964C>T
p.Arg322*
c.2201_2202
delAA
p.Lys734
Serfs*24
c.1441
C>T
p.
Arg481*
c.3053-3066del14
p.Gly1018
Aspfs*2
del exon1 c.1582delA
p.Arg
528Glufs*4
c.1882
C>T
p.Arg
628*
c.2725del
p.
Ala909Profs*13
c.652C>T
p.Arg218*
c.952C>T
p.Gln318*
c.3596_3597
insA
p.Lys
1199Asnfs
46,X,t(X;3)
(q13;q11)
c.1882C>T
p.Arg628*
c.964C>T
p.R322*
XCI 57:43
(random)
70:30
(random)
52:48
(random)
63:37
(random)
100%
skewing
62:38
(random)
64:36
(random)
100% skewing 65:35
(random)
73:27
(borderline
skewed)
KIAA2022
expression (ratio)
0.000624456 0.00029598 0.000355424 0.000256076 Absent Absent
Walking age
(months)
24 18 19 15 14,5 − 12 24 14 19 12 15 24 18 ? ? 12–18
Language skills Sentences Sentences Sentences Sentences Sentences Absent Full sentences Absent 150 words 5
words
Normal Two-word
phrases
Single
simple
words, no
sentences
Simple
sentences
Absent ? Two words
ID + + + + + + + + + + − + + + + + +
Degree of ID + + +/− + + to ++ + +/− to + + to ++ + +/− − + ++ + ++ +/− ++
Age at first notice
of delay (months)
18 8 From birth 30 12–24 3 35 15 12–18 7 − <20 12–24 12–18 ? ? 18
Autistic behaviour + + − + − − + + − − − + − − + ? +
Other
neurobehavioural
problems
− Aggression
hyperactive
Tantrums
hyperactive
ADHD Attention-deficit
hyperactive
− + Tantrums
hyper-active
Hyperactive,
impulse
control
difficulties
− − Severe ADHD,
impulse control
disorder
− Opposition − ? Repetitive
behaviours,
aggression,
hyperactive
Seizures + + + + + − + + + − + + + + − − +
Neurological
examination
Normal Normal Normal Normal Normal Hypotonia Normal Normal Normal tone
ataxic gait
Normal Normal Hypotonic,
broad-based
gate
Normal Normal ? ? Normal
Growth
retardation,
prenatal
− − − <−2SD − −2 SD − − − − − − − − p3–p10 ? −
Growth
retardation,
postnatal
− − − − − + − − − − − − + − + − +
Obesity + + + − − − − + − − − − + − − ? −
Microcephaly − − − − − + − − − − − − − − + ? +
Dysmorphisms − + − − − + − − − − − − + − + − +
Joint laxity + − − − − − − − − + − − − + − ?
Hypotonia − − − − − + Very mild − − + − + − Mild − ? −
Additional
medical problems
Hip dysplasia GER Neonatal
feeding
difficulties
− − GER − − Otitis media,
PFO
− IDDM,
horse-shoe
kidney
Cardiac
rhabdo-myoma,
TSC 1 and 2
negative
− Pulmonary
stenosis
Primary
amenorrhoea,
hyperglycaemia
? −
MRI brain Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal ? Normal Normal Frontal
atrophy
(3 years)
Morphological
alterations of
temporal lobes
? Status after
corpus
callosotomy
surgery
?, unknown.
ADHD, attention deficit hyperactivity disorder; GER, gastroeosophageal reflux; ID, intellectual disability; TSC, tuberous sclerosis complex; XCI, X-chromosome inactivation.
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Table 2 Clinical description of previously reported males carrying KIAA2022 mutations
Family Family 11 2 Family 22 Family 32 Family 42 Family 53 Family 63
Patient 1 2 3 4 5 6 7 8 9 10
Age (years) 13 20 6 4 8 14 10 40 3 5
Mutation InvX InvX Ser1200fs Ser1200fs Exon 1 dup Arg62fs Arg62fs Arg62fs Gln705* Arg322*
XCI n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
KIAA2022 expression Absent Absent ? ? 40% ? ? ? ? ?
Walking age (months) 36 36 34 48 17 18 18,5 14 − 48
Language skills Absent Absent Rudimentary Absent Rudimentary Delayed Poor Poor Absent Absent
ID + + + + + + + + + +
Degree of ID ++ ++ ++ ++ +/− + ++ + ++ ++
Age first notice of delay
(months)
0–12 0–12 0–12 0–12 ? ? ? 36 0–12 3
Autistic behaviour + + + + + − + − − +
Other neurobehavioural
problems
Self-biting hyperactive Aggressive
anxiety
− − + Hyperactive
attention-deficit
Aggressive, attention-deficit,
hyperactive
Hyperactive − −
Seizures − + + + − − + + − −
Syndrome diagnosis Lennox–Gastaut
Neurological exam Hypotonia Spastic
quadriplegia
Axial hypotonia,
lower limb
spasticity
Hypotonia, lower
limb spasticity
Normal Normal Normal Normal Hypotonia Hypotonia
Growth retardation,
prenatal
− − − − − − − − − −
Growth retardation,
postnatal
+ + + + − − − − + +
Obesity − − − − − − + + − −
Microcephaly + − + + − − − − − +
Dysmorphisms + + + + − − − ? + +
Joint laxity − − − − − − − ? − −
Hypotonia + + + + − − − ? + +
Additional medical
problems
GER GER, gastric
ulcer
GER GER gastrostomy − Bulimia GER Bulimia GER Nephrotic syndrome,
central hypothyroidism
MRI brain Small brain, mild
enlargement of sulci in
frontal lobes
Moderate brain
atrophy
? ? Normal Normal Normal ? Normal Normal
If features are not described in the original article, we assume they are not present. Note that more details on the female phenotypes were available in some cases.
−, absent; +/−, mild; +, moderate; ++, severe; ?, unknown.
GER, gastroeosophageal reflux; ID, intellectual disability; IDDM, insulin-dependent diabetes mellitus; n.a., not applicable; PFO, patent foramen ovale; XCI, X-chromosome inactivation.
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Table 3 Clinical description of female cases presented; detailed epilepsy phenotypes
Patient 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Ref. 9 Ref. 10 Ref. 11
Age 26 9 25 11 36 2,5 9 18 5,5 2,3 53 11 51
(deceased) 8,5
26 13 17
Mutation c.4185del p.
Lys 1396fs
c.438
C>A p.
Cys 146*
c.2042del
p.Gly681fs
c.964 C>T p.
Arg322*
c.2201_2202
delAA
p.Lys734
Serfs*24
c.1441
C>T
p.
Arg481*
c.3053-3066
del14 p.
Gly1018
Aspfs*2
del exon1 c.1582delA
p.Arg
528Glufs*4
c.1882C>T
p.Arg
628*
c.2725del
p.Ala909
Profs*13
c.652 C>T
p.Arg 218*
c.952C>T
p.Gln 318*
c.3596_3597
insA
p.Lys
1199Asnfs
46,X,t
(X;3)
(q13;
q11)
c.1882
C>T p.
Arg
628*
c.964C>T
p.R322*
XCI 57:43
(random)
70:30
(random)
52:48
(random)
63:37
(random)
100%
skewing
62:38
(random)
64:36
(random)
100%
skewing
65:35
(random)
73:27
(borderline
skewed)
KIAA2022
expression
(ratio)
0,000624456 0,00029598 0,000355424 0,000256076 Absent absent
Degree of ID +/− to + + +/− +/− + to ++ + +/− to + + to ++ + +/− − + ++ + ++ +/− ++
Seizures + + + + + − + + + − + + + + − − +
Age seizure
onset (months)
8 8 72 30 36 24 24 14 192–216 24 84 36 18
Generalised + + + + + − + − + − + + + + − − +
Myoclonic + + + + + − + − + − ? + + + − − ?
Typical absence − + + − + − + − + − + + − − − − +
Myoclonic
absence
− − + − − − + − + − ? − − + − − ?
Tonic − − − + − − − − + − − − − + − − +
Atonic − + − + − − − − + − − − + + − − +
Clonic − − − − − − − + − − − + − + − − −
GTCS + + + − + − − − + − − + + − − − +
Focal − + − + Probably not − − + − − − + − − − − −
Spasms − − − − − − − − − − − − − − − − −
Status
epilepticus
− + − ? + − ? + ? − ? + + − − − ?
Other seizure
types
− − − − − − Automatisms
(focal
seizures?)
− − − ? − − − − − ?
Photosensitivity − + + ? − − − − ? − − − ? − − − ?
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Three female patients affected by KIAA2022 disruptions
were previously reported. Moyses-Oliveira et al reported a
female patient with a balanced X-autosomal translocation dis-
rupting KIAA2022 at intron 1.9 XCI studies showed inactiva-
tion of the normal X-chromosome in all cells, leading to
complete absence of KIAA2022 expression. The reported
phenotype was comparable to the previously described male
phenotype, with severe ID, microcephaly, autistic behaviour,
growth retardation and facial dysmorphia, without epilepsy.
Athanasakis et al10 reported a 13-year-old girl with mild ID
and a de novo non-sense mutation of KIAA2022 (p.Arg628*)
as part of a larger study which included patients with ID and
absence of dysmorphic features, normal growth parameters
and no seizures or malformations. The X-inactivation pattern
was 65:35. Farach and Northrup11 reported a 17-year-old girl
with a recurrent de novo non-sense mutation of KIAA2022
previously reported in a male (p.Arg
322*) and a phenotype comparable to previously reported
male patients, with severe ID, hypotonia, behavioural pro-
blems, microcephaly, growth retardation, mild dysmorphisms
and seizures. An X-inactivation pattern of 73:27 was reported.
These previously reported female patients seem to be on the
extreme ends of the phenotypic spectrum in comparison to
our new cases, with one patient being relatively mildly
affected,10 while the other two have a phenotype comparable
to our most severely affected cases.9 11 Although we observe a
comparable clinical picture in most female cases, this illustrates
that the phenotypes of females affected by KIAA2022 muta-
tions can be very variable. Moreover, unaffected female car-
riers of KIAA2022 disruptions have been reported,2 and the
ExAC database includes three females with heterozygous
apparent LOF variants in KIAA2022.17
No inheritance or clinical data are available for the females
in the ExAC database, but it does not include patients with
paediatric onset ID.17 However, the presence of these variants
in the ExAC database might be explained by the nature of the
variants. Regarding the truncating alteration (Arg1469*), it
appears that this alteration will not undergo non-sense
mediated decay, as it is located at the end of the second to last
exon. Therefore, a truncated protein, lacking the last 48 amino
acids, will be produced, which may not be a complete LOF
alteration. The splice alteration is in the splice acceptor in the
last exon, and it might have minimal functional impact since it
is localised near the 30-end of the protein. The apparent hemi-
zygous frameshift variant (Arg1085fs) looks like an in-frame
indel that was miscalled (c.3245_3265del21insCCT; deletion
of 21 bp, insertion of 3 bp) upon manual visualisation.
Therefore, these reported variants are likely non-pathogenic.
Furthermore, it is worth noticing that ExAC variants are not
validated, and some of them could be false positives. On the
other hand, it is possible that these mutations are pathogenic
but that they occur in asymptomatic female carriers, as previ-
ously described.2
Although both males and females with KIAA2022 mutations
have ID and frequent autistic behaviour, males tend to have a
more severe phenotype. They have more severe ID (as opposed
to mild to severe in females) and more frequently microceph-
aly, hypotonia, growth retardation, feeding difﬁculties and
facial dysmorphisms. Epilepsy was reported in 5 of 10 male
patients, whereas it was seen in 13 of 17 females, making it a
more frequent clinical ﬁnding in females.1–3 It should be
noted, however, that some of our female patients (1, 2, 3 and
5) were selected for genetic testing because of their epilepsy,
which may have introduced a selection bias.
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A reduced penetrance and variable expression in females and
a more severe phenotype in males versus females is a common
observation in many X-linked disorders, and may be explained
by XCI patterns in females.18–22 Our female patient 6 and the
patient previously reported by Moyses-Oliveira et al9 support
this theory. Both had 100% skewed X-inactivation patterns and
complete loss of expression, leading to a phenotype closely
resembling the more severe male phenotype. Conversely, a pre-
viously reported male with the least severe phenotype among
reported males was shown to have a duplication of exon 1,
resulting in a decrease in expression of 60%.2 This is in contrast
to several other male patients that lack expression completely.
So far, the degree of KIAA2022 loss thus seems to correlate with
the severity of the phenotype, with complete loss of expression
predicting a severe phenotype. The patient reported by Farach
and Northrup11 had a borderline skewed X-inactivation (73:27)
and was also severely affected. In six out of seven tested female
patients, a random XCI was found, and expression of
KIAA2022 was on average two to three times lower than that in
female controls, although this was not statistically signiﬁcant.
These female patients all showed a similar clinical phenotype,
characterised by intractable myoclonic epilepsy and an ID that is
less severe than in male patients. The very mildly affected
patient described by Athanasakis et al10 also had a random
X-inactivation according to our criteria (65:35). These results
indicate that partial loss of KIAA2022 expression explains the
phenotype in those females who are more mildly affected than
males. Unfortunately, data on X-inactivation patterns are lacking
in patient 11, who has a very mild phenotype compared with
other affected females, and in the unaffected female carriers of
familial KIAA20022 disruptions. However, expression in at least
one unaffected female carrier was reported to be normal com-
pared with controls, suggesting XCI skewing towards the wild-
type allele as an explanation for their lack of symptoms.5 No
clinical data on unaffected female carriers are available.
Next to X-inactivation patterns in blood, other factors might
also explain the clinical variability in females with KIAA2022
mutations. First, X-inactivation and expression in blood might
not reﬂect what is occurring in the brain. Second, other factors
may modify expression, such as variants in regulatory sequences
of KIAA2022 and related genes, or a parent of origin effect.
Finally, mechanisms other than loss of expression might also
play a role in affected females. The random XCI found in
several female patients predicts a mosaic population of cells
with either normal or absent expression of KIAA2022, in con-
trast to male patients, where all cells have the defective allele.
Although this mosaic cell population in females may have
similar effects as the defect in males, an additional disease mech-
anism might be cellular interference, as is the proposed disease
mechanism in PCDH19-related epilepsy.23–26 In females,
PCDH19 mutations cause variable degrees of epilepsy,
Figure 1 Genomic organisation of KIAA2022 and location of mutations. Figure shows schematic presentation of known exon–intron organisation
of KIAA2022. Exon size is at a scale apart from exon 4, for which the arrow indicates the continued size. Untranslated regions are indicated by grey
colour, and the coding regions are indicated by blue colour. The boxes indicate the location and identity of the (previously) observed mutations in
female (lower/red boxes) and previously reported mutations in male patients (upper/green boxes).
Figure 2 Relative expression of KIAA2022 in four cases versus female
controls. Y-axis gives the ratio of positive droplets for KIAA2022 vs
GAPDH; experiment was done in triplicate. 95% CIs are indicated by
error bars.
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behavioural problems and intellectual deﬁcits, while male car-
riers are unaffected. However, one reported male with a female
phenotype was found to be mosaic for a PCDH19 mutation,
just as affected females.25 Brain mosaicism in females, as a result
of random X-inactivation, was proposed to disrupt cell–cell
interactions between the two different cell populations (the cells
with normal PCDH19 on the one hand, and the cells with
mutated PCDH19 on the other). A similar disease mechanism is
plausible, since the KIAA2022 protein seems to be involved in
the same processes of cell–cell and cell–matrix adhesion and
neuronal migration as the PCHD19 protein, by inﬂuencing
expression of N-cadherin.7 Additional X-inactivation and
expression studies of asymptomatic mothers of affected males
carrying KIAA2022 mutations could further clarify the disease
mechanism in females with KIAA2022-related disease.
CONCLUSION
In conclusion, we show that de novo truncating mutations in the
X-chromosomal KIAA2022 gene can lead to a phenotype in
males and in females. While males had more pronounced ID and
dysmorphic features, females with KIAA2022 mutations show
variable symptoms, and some are even asymptomatic. Females
with 100% XCI skewing and absent KIAA2022 expression show
a phenotype similar to the male phenotype. Females with
random XCI patterns tend to have a more prominent epilepsy
phenotype, with predominant generalised myoclonic and/or
absence seizures. Mechanisms underlying the female phenotype
may be both cellular mosaicism and reduced protein expression.
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